South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market (2025-2031) | Competitive Landscape, Segmentation, Industry, Companies, Forecast, Value, Outlook, Share, Growth, Size & Revenue, Analysis, Trends

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 South Africa Country Macro Economic Indicators

3.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, 2021 & 2031F

3.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market - Industry Life Cycle

3.4 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market - Porter's Five Forces

3.5 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.6 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

3.7 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By End User, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of pulmonary arterial hypertension (PAH) in South Africa

4.2.2 Growing awareness about PAH among healthcare professionals and patients

4.2.3 Rising investments in research and development for innovative PAH drugs

4.3 Market Restraints

4.3.1 High cost of PAH drugs leading to affordability issues for patients

4.3.2 Stringent regulatory requirements for drug approval in South Africa

6.1 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market, By Drug Class

6.1.1 Overview and Analysis

6.1.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F

6.1.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Endothelin Receptor Antagonists (ERAs), 2021- 2031F

6.1.4 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Vasodilators, 2021- 2031F

6.1.5 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Phosphodiesterase-5 (PDE-5) Inhibitors, 2021- 2031F

6.1.6 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Soluble Guanylate Cyclase (sGC) Stimulators, 2021- 2031F

6.1.7 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Calcium Channel Blockers (CCBs), 2021- 2031F

6.1.8 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Prostacyclin and Prostacyclin Analogs, 2021- 2031F

6.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market, By Route of Administration

6.2.1 Overview and Analysis

6.2.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Inhalation, 2021- 2031F

6.2.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Injectable, 2021- 2031F

6.2.4 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Oral Administration, 2021- 2031F

6.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market, By End User

6.3.1 Overview and Analysis

6.3.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F

6.3.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Clinics, 2021- 2031F

7.1 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Export to Major Countries

7.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Imports from Major Countries

8.1 Patient adherence rate to prescribed PAH medications

8.2 Number of new PAH drug approvals in South Africa

8.3 Rate of adoption of advanced PAH treatments in healthcare facilities

8.4 Patient satisfaction with the efficacy and side effects of PAH drugs

8.5 Percentage of healthcare professionals trained in diagnosing and managing PAH

9.1 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

9.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By End User, 2021 & 2031F

10.1 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue Share, By Companies, 2024

10.2 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Benchmarking, By Operating and Technical Parameters